Mechanical Circulatory Support with Abiomed BVS 5000 and BioMedicus BP–80 for Postcardiotomy Cardiogenic Shock

2001 ◽  
pp. 445-448 ◽  
Author(s):  
A Sezai ◽  
K Minami ◽  
A El-Banayosy ◽  
L Arusoglu ◽  
P Sarnowsky ◽  
...  
Keyword(s):  
Cardiogenic Shock ◽  
Mechanical Circulatory Support ◽  
Circulatory Support ◽  
Postcardiotomy Cardiogenic Shock

Mechanical circulatory support with the Impella 5.0 and the Impella Left Direct pumps for postcardiotomy cardiogenic shock at La Pitié-Salpêtrière Hospital

2019 ◽  
Vol 57 (1) ◽  
pp. 183-188 ◽  
Author(s):  
Charles-Henri David ◽  
Astrid Quessard ◽  
Ciro Mastroianni ◽  
Guillaume Hekimian ◽  
Julien Amour ◽  
...  
Keyword(s):  
Cardiogenic Shock ◽  
Mechanical Circulatory Support ◽  
Heart Function ◽  
Left Ventricular ◽  
Survival Outcome ◽  
Ventricular Assist Devices ◽  
Circulatory Support ◽  
Left Ventricular Assist Devices ◽  
The Mean ◽  
Postcardiotomy Cardiogenic Shock

Abstract OBJECTIVES Postcardiotomy cardiogenic shock (PCCS) is associated with high mortality rates of 50–80%. Although veno-arterial extracorporeal membrane oxygenation has been used as mechanical circulatory support in patients with PCCS, it is associated with a high rate of complications and poor quality of life. The Impella 5.0 and Impella Left Direct (LD) (Impella 5.0/LD) are minimally invasive left ventricular assist devices that provide effective haemodynamic support resulting in left ventricular unloading and systemic perfusion. Our goal was to describe the outcome of patients with PCCS supported with the Impella 5.0/LD at La Pitié-Salpêtrière Hospital. METHODS We retrospectively reviewed consecutive patients supported with the Impella 5.0/LD for PCCS between December 2010 and June 2015. Survival outcome and in-hospital complications were assessed. RESULTS A total of 29 patients (63 ± 14 years, 17% women) with PCCS were supported with the Impella 5.0/LD. At baseline, 69% experienced chronic heart failure, 66% had dilated cardiomyopathy and 57% had valvular disease. The mean EuroSCORE II was 22 ± 17 and the ejection fraction was 28 ± 11%. Most of the patients underwent isolated valve surgery (45%) or isolated coronary artery bypass grafting (38%). The mean duration of Impella support was 9 ± 7 days. Weaning from the Impella was successful in 72.4%, and 58.6% survived to discharge. Recovery of native heart function was observed in 100% of discharged patients. Survival to 30 days and to 1 year from Impella implant was 58.6% and 51.7%, respectively. CONCLUSIONS The Impella 5.0 and the Impella LD represent an excellent treatment option for critically ill patients with PCCS and are associated with favourable survival outcome and native heart recovery.

Mechanical circulatory support with the thoratec assist device in patients with postcardiotomy cardiogenic shock

1996 ◽  
Vol 61 (1) ◽  
pp. 314-316 ◽  
Author(s):  
Reiner Körfer ◽  
Aly El-Banayosy ◽  
Herbert Posival ◽  
Kazutomo Minami ◽  
Lukas Kizner ◽  
...  
Keyword(s):  
Cardiogenic Shock ◽  
Mechanical Circulatory Support ◽  
Circulatory Support ◽  
Assist Device ◽  
Postcardiotomy Cardiogenic Shock

scholarly journals MECHANICAL CIRCULATORY SUPPORT (MCS) FOR POSTCARDIOTOMY CARDIOGENIC SHOCK IN INFANTS

ASAIO Journal ◽  
1996 ◽  
Vol 42 (2) ◽  
pp. 34
Author(s):  
K. Ishino ◽  
V. Alexi-Meskishvili ◽  
Y. Weng ◽  
M. Loebe ◽  
F. Uh lemann ◽  
...  
Keyword(s):  
Cardiogenic Shock ◽  
Mechanical Circulatory Support ◽  
Circulatory Support ◽  
Postcardiotomy Cardiogenic Shock

Effective Mechanical Circulatory Support with Impella in Postcardiotomy Cardiogenic Shock

2017 ◽  
Vol 36 (4) ◽  
pp. S434
Author(s):  
D.G. Tang ◽  
G.W. Vetrovec ◽  
C. Toma ◽  
A.B. Civitello ◽  
M. Silver ◽  
...  
Keyword(s):  
Cardiogenic Shock ◽  
Mechanical Circulatory Support ◽  
Circulatory Support ◽  
Postcardiotomy Cardiogenic Shock
Sign in / Sign up

Export Citation Format

Share Document